Clinical trial design for invasive aspergillosis: Time to cast a different mold

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Miceli, Marisa ^a   Anaissie, Elias J ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antifungal agents; Clinical trials; Galactomannan; Invasive aspergillosis

Indexed keywords

ANTIFUNGAL AGENT; GALACTOMANNAN;

ARTICLE; AUTOPSY; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DISEASE MARKER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LUNG ASPERGILLOSIS; LUNG LAVAGE; OUTCOME ASSESSMENT; PATIENT SELECTION; SENSITIVITY AND SPECIFICITY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ASPERGILLUS;

ANTIFUNGAL AGENTS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67651090091     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780902718057     Document Type: Article

References (37)

1. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173: 707-717.
2. Anaissie EJ. Trial design for mold-active agents: Time to break the mold - aspergillosis in neutropenic adults. Clin Infect Dis 2007; 44 1298-1306.
3. Steinbach WJ, Loeffler J, Stevens D. Aspergillosis. In: Wingard JR, Anaissie E (eds). Fungal Infections in the Immunocompromised Patient New York: Taylor & Francis Group, 2005: 257-294.
4. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
5. Subira M, Martino R, Rovira M, et al. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsyconfirmed invasive aspergillosis. Ann Hematol 2003; 82: 80-82.
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
7. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
8. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406-1412.
9. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-366.
10. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer 2007; 110: 112-120.
11. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-1336.
12. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-3228.
13. Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121: 448-457.
14. Chmura Kraemer H, Periyakoil VS, Noda A. Kappa coefficients in medical research. Stat Med 2002; 21: 2109-2129.
15. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: Clinical and research implications. Clin Infect Dis 2008; 46: 1412-1422.
16. Woods G, Miceli MH, Grazziutti ML, et al. Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: A study of 56 patients with hematologic cancer. Cancer 2007; 110: 830-834.
17. Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 2006; 8: 128-139.
18. Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42: 4744-4748.
19. El Saleeby CM, Allison KJ, Knapp KM, Walsh TJ, Hayden RT. Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure, and ongoing hemodialysis. J Clin Microbiol 2005; 43: 3560-3563.
20. Murashige N, Kami M, Kishi Y, Fujisaki G, Tanosaki R. Falsepositive results of Aspergillus enzyme-linked immunosorbent assays for a patient with gastrointestinal graft-versus-host disease taking a nutrient containing soybean protein. Clin Infect Dis 2005; 40 333-334.
21. Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325-327.
22. Mennink-Kersten MA, Ruegebrink D, Klont RR, et al. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol 2005; 43: 3925-3931.
23. Dalle F, Charles PE, Blanc K, et al. Cryptococcus neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 2005; 43: 2929-2931.
24. Ulusakarya A, Chachaty E, Vantelon JM, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1: 111-116.
25. Verweij PE, Dompeling EC, Donnelly JP, Schattenberg AV, Meis JF. Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection 1997; 25: 86-89.
26. Salonen J, Lehtonen OP, Terasjarvi MR, Nikoskelainen J. Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infect Dis 2000; 32: 485-490.
27. Rovira M, Jimenez M, De La Bellacasa JP, et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: A prospective study. Transplantation 2004; 77: 1260-1264.
28. Moragues MD, Amutio E, Garcia-Ruiz JC, Ponton J. Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis. Rev Iberoam Micol 2003; 20: 103-110.
29. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
30. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 2001; 97: 1604-1610.
31. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1->3)-beta-d-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42: 2733-2741.
32. Walsh TJ. The low rate of false positive and false negative of GMI in infected animals who underwent autopsy examination revealing both histopathologic and microbiologic evidence of aspergillosis and in uninfected control in experimental studies. In: Anaissie E (ed.), 2006. Personal communication. Author: Walsh T.J; Receipient: Anaissie E.J.; Washington D.C. USA.
33. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-1769.
34. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis 2004; 190: 641-649.
35. Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005; 41: S381-S386.
36. Schafer H, Timmesfeld N, Muller HH. An overview of statistical approaches for adaptive designs and design modifications. Biom J 2006; 48: 507-520.
37. Gottlieb S. Remarks on Adaptive Trial Design, 2006 Conference on Adaptive Trial Design, Washington, DC. In: http://www.fda.gov/oc/ speeches/2006/trialdesign0710.html, 10 July 2006.